Core Insights - BioVaxys Technology Corp. has integrated the DPX™ platform into its operations, focusing on organic growth and innovative vaccine development that enhances immune response through a novel mechanism of action [1][5]. Company Developments - The company appointed Dr. James Tartaglia and Dr. Marianne Stanford to its Board and as Scientific Advisor, respectively, enhancing its scientific and business development expertise [2][3][4]. - Dr. Tartaglia has over 34 years of experience in vaccine R&D, having led vaccine development at Sanofi, while Dr. Stanford previously led the development of the DPX™ vaccine portfolio at IMV Inc [3][4]. Clinical Studies - BioVaxys reported positive results from a Phase 1 study of maveropepimut-S (MVP-S) in HR+/HER2- stage II-III breast cancer, showing a significant immune response and a decrease in Ki67 levels from a median of 24% to 6% post-treatment [7][8]. - The company plans to further evaluate MVP-S's systemic immunity and pursue a Phase II study to modify the tumor immune environment in high-risk HR+ breast cancer [9]. Collaborations and Licensing - BioVaxys entered a research agreement with Sona Nanotech to develop new cancer therapeutics combining the DPX platform with Sona's Targeted Hyperthermia Therapy™ [10]. - The company is exploring out-licensing opportunities for MVP-S, particularly for ovarian cancer, and is in discussions with a global pharma company [11][12]. Pipeline Expansion - BioVaxys is advancing its early-stage pipeline with multiple out-licensing opportunities and research collaborations, including a DPX formulation for rabies and a DPX-RSV vaccine that demonstrated antigen-specific immune responses in 93% of subjects [6][14]. - The company is also developing additional infectious disease programs, including DPX-rHA/DPX-FLU for influenza and DPX-rPA for anthrax, with promising preclinical results [15]. Revenue Generation - BioVaxys has revenue-generating licenses with Zoetis Inc. and SpayVac for Wildlife, Inc., focusing on vaccines in the animal health field, with ongoing progress towards commercialization [17][18]. - SpayVac has initiated the regulatory approval process for its immunocontraceptive vaccine targeting feral horses and deer populations, which is based on BioVaxys's technology [18][20]. Future Outlook - The company anticipates aggressive business development activity in 2026, aiming to advance ongoing out-licensing and research collaboration discussions, and to book its first royalty income [22].

Summary of Key Points Core Viewpoint - Headwater Gold Inc. has granted 1,825,000 incentive stock options to its directors, officers, employees, and consultants, which are exercisable at a price of $0.75 for a five-year term and vest immediately [1]. Group 1 - The total number of stock options granted is 1,825,000 [1]. - Each option allows the purchase of one common share at a price of $0.75 [1]. - The options have a term of five years and vest immediately upon grant [1].

Core Viewpoint - Golden Lake Exploration Inc. has entered into a new mining lease agreement with GM Squared, LLC for the Jewel Ridge project in Nevada, which includes both unpatented and patented mining claims, replacing a previous lease from 2004 [1][2]. Lease Agreement Details - The Lease Agreement has a duration of 7 years, requiring annual payments of US$25,000 and a minimum expenditure of US$1 million on mining and exploration activities in the first 3 years [2]. - The Company has the option to purchase the property for US$3 million, deducting the total lease payments made during the agreement [3]. - Upon production commencement, the Company will pay a royalty of 4.0% on net smelter returns, with options to buy down the royalty at specified costs for each percentage point [4]. Termination Conditions - The Company can terminate the Lease Agreement with 30 days written notice, while the Lessor can terminate if the Company defaults on obligations, including payment failures [5]. Additional Claims and Royalties - The Jewel Ridge project includes 19 patented claims (Rainbow Claims) acquired from Greencastle Resources Ltd., subject to a 3.0% royalty, which can be reduced to 1.0% for C$2 million [6]. - In April 2022, the Company added the Lord Byron patented claims, which do not carry any royalties or obligations [7]. - In September 2023, the Company staked an additional 46 unpatented lode claims totaling 924 acres, fully owned without royalty obligations [8]. Company Overview - Golden Lake Exploration Inc. is a junior public mining exploration company focused on mineral exploration and acquisition of mineral property assets [9].

Core Viewpoint - Adamera Minerals Corp. has successfully closed the flow-through portion of its private placement, raising a total of $253,500 through the sale of Flow-Through Units [1][2]. Group 1: Financial Details - The company raised $253,500 from the sale of 3,900,001 Flow-Through Units at a price of $0.065 per unit [2]. - Each Flow-Through Unit consists of one common share and one-half common share purchase warrant, with full warrants exercisable at $0.12 for two years [2]. - The warrants will expire if the closing market price of the common shares reaches $0.16 or more for 10 consecutive trading days, triggering an Accelerated Expiry Date [2]. Group 2: Use of Funds - The funds raised will be allocated for qualifying Canadian exploration expenditures on newly identified gold, copper, and zinc prospects at the South Hedley Project in southern British Columbia [3]. - The financing may be eligible for a 30% Critical Mineral Exploration Tax Credit [3]. Group 3: Related Party Transactions - A director and an officer of the company acquired a total of 507,693 Flow-Through Units under the private placement, constituting a related party transaction [4]. - The company has relied on exemptions from formal valuation and minority shareholder approval requirements due to the transaction's value not exceeding 25% of the company's market capitalization [4]. Group 4: Future Plans - The company plans to close the non-flow-through units of the private placement announced earlier in early 2026 [5]. Group 5: Company Overview - Adamera Minerals Corp. focuses on exploring high-grade gold deposits in Washington State and British Columbia, holding numerous drill-ready targets in areas with past producing mines [5].

Core Viewpoint - Viva Gold Corp. has successfully completed a non-brokered private placement, raising gross proceeds of CDN$4,183,273 through the issuance of 26,145,456 units, which will be utilized for advancing the Tonopah Gold Project [1][2]. Group 1: Offering Details - The Offering consisted of 26,145,456 units priced at CDN$0.16 each, with each unit comprising one common share and one-half of a non-transferable common share purchase warrant [1]. - Each whole warrant is exercisable at CDN$0.24 per share until December 29, 2028, which is 36 months from issuance [1]. - Insiders acquired 6,490,956 units, qualifying as a "related party transaction" but exempt from formal valuation and minority shareholder approval due to the transaction's size relative to the company's market capitalization [3]. Group 2: Use of Proceeds - The proceeds from the Offering will primarily fund pre-feasibility and feasibility studies at the Tonopah Gold Project, including necessary technical and environmental studies [4]. - Additional allocations include geophysical surveys, geological work, and general working capital [4]. Group 3: Finder's Fees - The Company will pay finder’s fees totaling CDN$84,154 and issue 525,962 Finder's Warrants, each exercisable at CDN$0.24 per share until December 29, 2028 [5]. Group 4: Regulatory Approval - The Offering is subject to final approval from the TSX Venture Exchange, and the securities issued will be under a statutory hold period of four months and one day from the issuance date [6]. Group 5: Company Overview - Viva Gold's Tonopah Gold Project is strategically located in a prominent mining area in Nevada, with a developed high-confidence gold mineral resource and potential for an economically viable open pit project [10]. - The Company is led by experienced professionals, including CEO James Hesketh, who has extensive experience in mining development and construction [10].

Core Viewpoint - Ventripoint Diagnostics Ltd. is conducting a non-brokered private placement to raise up to $500,000 through the issuance of 5,000,000 units at a price of $0.10 per unit, subject to regulatory approval [1][5]. Group 1: Offering Details - Each unit consists of one common share and one common share purchase warrant, with the warrants allowing the purchase of additional shares at $0.13 for 24 months [2]. - The corporation may pay a cash finder's fee and issue finder's warrants up to 8% of the gross proceeds, with each finder's warrant also exercisable at $0.13 for 24 months [3]. - The proceeds from the offering will be allocated to operational costs, sales and marketing, hiring key personnel, and general working capital [4]. Group 2: Regulatory and Compliance Information - All securities issued will be subject to a hold period of four months plus one day from the closing date of the offering [5]. - The securities will not be registered under the U.S. Securities Act of 1933 and cannot be offered or sold in the United States without proper registration or exemption [6]. Group 3: Company Overview - Ventripoint has established itself as a leader in applying AI to echocardiography, with its VMS+ products providing accurate cardiac measurements comparable to MRI [8]. - The technology is a cost-effective alternative that enhances cardiologists' confidence in patient management and is compatible with all ultrasound systems from various vendors, supported by regulatory approvals in the U.S., Europe, and Canada [8].

Core Insights - Lexaria Bioscience Corp. has released additional data from its Phase 1b clinical study GLP-1-H24-4, which focuses on the efficacy of its DehydraTECH™ technology compared to Rybelsus® [1][2] Secondary Efficacy Parameters - At week 16, the DHT arms showed no statistically significant differences compared to the Rybelsus® control in mean fasting glucose, cholesterol, and LDL cholesterol [3] Body Composition - The DHT-semaglutide arm showed a modest reduction in fat mass of -1.08 kg and total mass of -1.40 kg, while the Rybelsus® control arm achieved greater reductions of -3.55 kg in fat mass and -5.36 kg in total mass, with a higher reduction in lean mass of -1.72 kg [4] Blood Pressure Analyses - The DHT-CBD arm achieved significant reductions in blood pressure, with a mean change of -4.6 mmHg in systolic and -4.0 mmHg in diastolic blood pressure at week 4 [5][6] Pharmacokinetic Exploratory Analyses - Plasma CBD concentrations were quantifiable through week 16 in the DHT-CBD arms, while semaglutide concentrations were not quantifiable due to assay issues, although preliminary tests indicated measurable levels [8] Health Survey Results - Participants in the DHT-semaglutide arm reported mean improvements of over 5 points in physical components and over 3 points in mental components of the SF-36 health survey, compared to modest improvements in the Rybelsus® control arm [9][10] Overall Conclusions and Next Steps - The study met its primary endpoint, demonstrating good safety and tolerability of all DHT test articles, with positive findings across various parameters compared to Rybelsus® [11] Future Plans - Lexaria plans to pursue further clinical testing with a DHT + SNAC + semaglutide composition and is in discussions with a pharmaceutical company regarding the dataset from the study [15][17][18]

 Vancouver, British Columbia – TheNewswire - December 30, 2025 – Muzhu Mining Ltd. (CSE: MUZU) (OTCPK: MUZU.F) (FSE:Y33) (the “Company”), is pleased to announce that pursuant to a directors’ resolution that was passed on December 19, 2025, the Company’s board of directors has approved the name change of the Company from “Muzhu Mining Ltd.” to “North Atlantic Titanium Corp.” (the “Name Change”). The Name Change aligns with the Company’s strategic focus to advance the Everett titanium deposit in Quebec.  In ...

Core Viewpoint - Neurothera Labs Inc. has received a patent from the Israel Patent Office for its proprietary combination of opioids and N-acylethanolamines, aimed at enhancing the therapeutic effects of opioids while reducing side effects [1][2]. Group 1: Patent and Technology - The newly granted patent in Israel complements existing patents in Europe, Japan, Australia, and Canada, thereby strengthening the global intellectual property protection for Neurothera's opioid-based platform [2]. - The patented technology utilizes N-acylethanolamines, such as palmitoylethanolamide (PEA), to enhance opioid analgesia through synergistic mechanisms, allowing for effective pain relief at lower doses [2]. Group 2: Research and Efficacy - A pre-clinical study evaluated the nociceptive effect of PEA combined with opiates like oxycodone, demonstrating that the proprietary drug combination could reduce adverse psychoactive effects associated with oxycodone [3][4]. - The study found that PEA not only mitigated some negative side effects of oxycodone but also prolonged its analgesic effects across all doses tested [4]. Group 3: Market Context - The global market for oxycodone drugs is projected to be valued between $5.5 billion and $5.7 billion in 2024, highlighting the significant sales potential despite the risks associated with opioid use [5]. - The "opioid-sparing" effect of Neurothera's combination may lead to reduced opioid dosages, potentially addressing issues like addiction and respiratory depression [6]. Group 4: Company Perspective - The CEO of Neurothera emphasized the importance of the patent grant, which validates the advantages of their proprietary combination in providing effective pain relief while ensuring patient safety [7].

Core Insights - Cascade Copper Corp. has outlined its strategic plans for 2026, building on a productive year in 2025 with advancements in exploration and financing [2][4] 2025 Highlights: Building Momentum in Exploration and Financing - The company raised over $1 million through multiple tranches of non-brokered private placements, including $401,255 in October and an oversubscribed placement of $660,000 in December for upcoming exploration programs [3] - Cascade completed a high-resolution drone magnetic survey covering over 700 line kilometers at the Centrefire Copper-Gold Project and submitted a work program permit, with a drill permit expected within 60 days [3] - High-grade samples of copper, gold, molybdenum, and silver were collected at the Copper Plateau Porphyry Project, confirming historic soil anomalies [3] - The introduction of the Bendor Gold-Tungsten Project included an initial compilation of historical data revealing notable values and the initiation of 3D magnetic inversion modeling [3] - A collaboration with Blockware Technology was announced to utilize AI for predictive mapping, enhancing exploration efficiency [3] 2026 Plans: Advancing Key Projects while Pursuing Value-Added Opportunities - Cascade Copper aims to accelerate exploration across its flagship properties while evaluating strategic transactions to enhance shareholder value [4] - Planned activities include responsible exploration practices and the continuation of drilling programs across several projects, including Centrefire, Copper Plateau, Fire Mountain, and Bendor [9]